velimogene aliplasmid
Trade name: allovectin
Vaccineexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Jul 1, 1998 (NCT00003647)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108663 ↗
Also known as
- allovectin
- allovectin-7
- velimogene aliplasmid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00395070 | Phase 3 | Oct 1, 2006 | Vical |
| NCT00050388 | Phase 3 | Dec 6, 2002 | Vical |
| NCT00044356 | Phase 2 | Feb 1, 2001 | Vical |
| NCT00003646 | Phase 2 | Aug 1, 1998 | Vical |
| NCT00003647 | Phase 3 | Jul 1, 1998 | Vical |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vical | For profit | 5 | 5 | 2 | 1998 |
1 organizations
Page 1 / 1